Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease

Neuropharmacology

Volumn 95, Issue , 2015, Pages 367-376

  Chiu, W H ^a   Depboylu, C ^a   Hermanns, G ^a   Maurer, L ^a   Windolph, A ^a   Oertel, W H ^a   Ries, V ^a   Hoglinger G U ^a,b,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

6 Hydroxydopamine; Adult neurogenesis; Hippocampal dentate gyrus; l DOPA; Olfactory bulb; Parkinson's disease; Pramipexole

Indexed keywords

BENSERAZIDE; LEVODOPA; PRAMIPEXOLE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL MIGRATION; CEREBELLUM GRANULAR LAYER; CIRCADIAN RHYTHM; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE GYRUS; DEPRESSION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FORCED SWIM TEST; HABITUATION; HIPPOCAMPUS; HISTOPATHOLOGY; HYPOSMIA; LATENT PERIOD; LONG TERM CARE; MALE; MEMORY; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NEWBORN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLFACTORY BULB; PARKINSON DISEASE; PRIORITY JOURNAL; ROTAROD TEST; SOCIAL INTERACTION TEST; STEM CELL; SUBSTANTIA NIGRA; SYMPTOM; ANIMAL; ANXIETY; C57BL MOUSE; DRUG EFFECTS; NERVE CELL; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION;

ANIMALS; ANTIPARKINSON AGENTS; ANXIETY; BENZOTHIAZOLES; DEPRESSION; HIPPOCAMPUS; LEVODOPA; MALE; MICE, INBRED C57BL; NEUROGENESIS; NEURONS; OLFACTORY BULB; OXIDOPAMINE; PARKINSONIAN DISORDERS; RANDOM ALLOCATION;

EID: 84928802705     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.03.020     Document Type: Article

References (77)

1. J. Altman Autoradiographic and histological studies of postnatal neurogenesis. IV. Cell proliferation and migration in the anterior forebrain, with special reference to persisting neurogenesis in the olfactory bulb J. Comp. Neurol. 137 1969 433 457
2. D. Alvarez-Fischer, C. Henze, C. Strenzke, J. Westrich, B. Ferger, G.U. Höglinger, W.H. Oertel, and A. Hartmann Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice Exp. Neurol. 210 2008 182 193
3. S.A. Baker, K.A. Baker, and T. Hagg Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone Eur. J. Neurosci. 20 2004 575 579
4. P. Barone, W. Poewe, S. Albrecht, C. Debieuvre, D. Massey, O. Rascol, E. Tolosa, and D. Weintraub Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol. 9 2010 573 580
5. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J. Neurol. Sci. 20 1973 415 455
6. A. Bonito-Oliva, M. Pignatelli, G. Spigolon, T. Yoshitake, S. Seiler, F. Longo, S. Piccinin, J. Kehr, N.B. Mercuri, R. Nistico, and G. Fisone Cognitive impairment and dentate gyrus synaptic dysfunction in experimental Parkinsonism Biol. Psychiatry 75 2013 701 710
7. A. Borta, and G.U. Hoglinger Dopamine and adult neurogenesis J. Neurochem. 100 2007 587 595
8. I. Branchi, I. D'Andrea, M. Armida, T. Cassano, A. Pezzola, R.L. Potenza, M.G. Morgese, P. Popoli, and E. Alleva Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model J. Neurosci. Res. 86 2008 2050 2061
9. A.A. Braun, D.L. Graham, T.L. Schaefer, C.V. Vorhees, and M.T. Williams Dorsal striatal dopamine depletion impairs both allocentric and egocentric navigation in rats Neurobiol. Learn. Mem. 97 2012 402 408
10. L. Brusa, A. Bassi, A. Stefani, M. Pierantozzi, A. Peppe, M.D. Caramia, L. Boffa, S. Ruggieri, and P. Stanzione Pramipexole in comparison to l-dopa: a neuropsychological study J. Neural Transm. 110 2003 373 380
11. K.A. Burns, and C.Y. Kuan Low doses of bromo- and iododeoxyuridine produce near-saturation labeling of adult proliferative populations in the dentate gyrus Eur. J. Neurosci. 21 2005 803 807
12. A.A. Castro, B.P. Wiemes, F.C. Matheus, F.R. Lapa, G.G. Viola, A.R. Santos, C.I. Tasca, and R.D. Prediger Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease Brain Res. 1513 2013 103 116
13. K.R. Chaudhuri, and A.H. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol. 8 2009 464 474
14. W.-H. Chiu, T. Carlsson, C. Depboylu, G.U. Höglinger, W.H. Oertel, and V. Ries Selegiline normalizes, while L-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease Neuropharmacology 79 2014 212 221
15. A. Costa, A. Peppe, G. Dell'Agnello, C. Caltagirone, and G.A. Carlesimo Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory Neuropsychologia 47 2009 1374 1381
16. C. Costa, C. Sgobio, S. Siliquini, A. Tozzi, M. Tantucci, V. Ghiglieri, M. Di Filippo, V. Pendolino, A. de Iure, M. Marti, M. Morari, M.G. Spillantini, E.C. Latagliata, T. Pascucci, S. Puglisi-Allegra, F. Gardoni, M. Di Luca, B. Picconi, and P. Calabresi Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease Brain 135 2012 1884 1899
17. L. Crews, H. Mizuno, P. Desplats, E. Rockenstein, A. Adame, C. Patrick, B. Winner, J. Winkler, and E. Masliah Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice J. Neurosci. 28 2008 4250 4260
18. C. Depboylu, L. Maurer, A. Matusch, G. Hermanns, A. Windolph, M. Behe, W.H. Oertel, and G.U. Hoglinger Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [(123)I]FP-CIT SPECT and histochemistry Neuroimage 79 2013 191 200
19. C. Depboylu, S. Stricker, J.P. Ghobril, W.H. Oertel, J. Priller, and G.U. Hoglinger Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease Exp. Neurol. 238 2012 183 191
20. F. Du, R. Li, Y. Huang, X. Li, and W. Le Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons Eur. J. Neurosci. 22 2005 2422 2430
21. P.S. Eriksson, E. Perfilieva, T. Björk-Eriksson, A.M. Alborn, C. Nordborg, D.A. Peterson, and F.H. Gage Neurogenesis in the adult human hippocampus Nat. Med. 4 1998 1313 1317
22. K.L. Eskow Jaunarajs, J.A. George, and C. Bishop L-DOPA-induced dysregulation of extrastrital dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease Neuroscience 218 2012 243 256
23. S. Fahn The history of dopamine and levodopa in the treatment of Parkinson's disease Mov. Disord. 23 Suppl. 3 2008 S497 S508
24. M. Favier, T. Duran, C. Carcenac, G. Drui, M. Savasta, and S. Carnicella Pramipexole reverses Parkinson's disease-related motivational deficits in rats Mov. Disord. 29 2014 912 920
25. B. Ferger, K. Buck, M. Shimasaki, E. Koros, P. Voehringer, and E. Buerger Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats Synapse 64 2010 533 541
26. J. Fernandez-Ruiz, D. Doudet, and T.G. Aigner Spatial memory improvement by levodopa in Parkinsonian MPTP-treated monkeys Psychopharmacology 147 1999 104 107
27. M.M. Ferro, M.I. Bellissimo, J.A. Anselmo-Franci, M.E. Angellucci, N.S. Canteras, and C. Da Cunha Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations J. Neurosci. Methods 148 2005 78 87
28. S.E. File, and P. Seth A review of 25 years of the social interaction test Eur. J. Pharmacol. 463 2003 35 53
29. N. Freundlieb, C. Francois, D. Tande, W.H. Oertel, E.C. Hirsch, and G.U. Hoglinger Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates J. Neurosci. 26 2006 2321 2325
30. F.H. Gage Mammalian neural stem cells Science 287 2000 1433 1438
31. A. Garthe, and G. Kempermann An old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis Front. Neurosci. 7 2013 63
32. A. Gasbarri, A. Sulli, and M.G. Packard The dopaminergic mesencephalic projections to the hippocampal formation in the rat Prog. Neuropsychopharmacol. Biol. Psychiatry 21 1997 1 22
33. A. Heuer, G.A. Smith, M.J. Lelos, E.L. Lane, and S.B. Dunnett Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites Behav. Brain Res. 228 2012 30 43
34. K.M. Hinkle, M. Yue, B. Behrouz, J.C. Dachsel, S.J. Lincoln, E.E. Bowles, J.E. Beevers, B. Dugger, B. Winner, I. Prots, C.B. Kent, K. Nishioka, W.L. Lin, D.W. Dickson, C.J. Janus, M.J. Farrer, and H.L. Melrose LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors Mol. Neurodegener. 7 2012 25
35. T. Hiramoto, Y. Kanda, Y. Satoh, K. Takishima, and Y. Watanabe Dopamine D2 receptor stimulation promotes the proliferation of neural progenitor cells in adult mouse hippocampus Neuroreport 18 2007 659 664
36. E. Hirsch, A.M. Graybiel, and Y.A. Agid Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334 1988 345 348
37. G.U. Höglinger, O. Arias-Carrion, B. Ipach, and W.H. Oertel Origin of the dopaminergic innervation of adult neurogenic areas J. Comp. Neurol. 10 2014 2336 2348
38. G.U. Höglinger, P. Rizk, M.P. Muriel, C. Duyckaerts, W.H. Oertel, I. Caille, and E.C. Hirsch Dopamine depletion impairs precursor cell proliferation in Parkinson disease Nat. Neurosci. 7 2004 726 735
39. H. Honig, A. Antonini, P. Martinez-Martin, I. Forgacs, G.C. Faye, T. Fox, K. Fox, F. Mancini, M. Canesi, P. Odin, and K.R. Chaudhuri Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life Mov. Disord. 24 2009 1468 1474
40. E. Huisman, H.B.M. Uylings, and P.V. Hoogland A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease Mov. Disord. 19 2004 687 692
41. A. Kern, R. Albarran-Zeckler, H.E. Walsh, and R.G. Smith Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism Neuron 73 2012 317 332
42. K. Kitagawa, Y. Kitamura, T. Miyazaki, J. Miyaoka, H. Kawasaki, M. Asanuma, T. Sendo, and Y. Gomita Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats Naunyn-Schmied Arch. Pharmacol. 380 2009 59 66
43. H.J. Kim, S.Y. Park, Y.J. Cho, K.S. Hong, J.Y. Cho, S.Y. Seo, D.H. Lee, and B.S. Jeon Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment J. Neurol. Sci. 287 2009 200 204
44. Z. Kohl, B. Winner, K. Ubhi, E. Rockenstein, M. Mante, M. Munch, C. Barlow, T. Carter, E. Masliah, and J. Winkler Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model Eur. J. Neurosci. 35 2012 10 19
45. P. Lagos, C. Scorza, J.M. Monti, H. Jantos, M. Reyes-Parada, R. Silveira, and A. Ponzoni Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats Eur. Neuropsychopharmacol. 8 1998 113 120
46. G. Liebsch, A.C. Linthorst, I.D. Neumann, J.M. Reul, F. Holsboer, and R. Langraf Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high- and low-anxiety-related behavior Neuropsychopharmacology 19 1998 381 396
47. D.W. Luchtman, Q. Meng, and C. Song Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease Behav. Brain Res. 226 2012 386 396
48. F. Marxreiter, B. Ettle, V.E. May, H. Esmer, C. Patrick, C.L. Kragh, J. Klucken, B. Winner, O. Riess, J. Winkler, E. Masliah, and S. Nuber Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice Neurobiol. Dis. 59C 2013 38 51
49. S. Merlo, P.L. Canonico, and M.A. Sortino Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype Neuropharmacology 60 2011 892 900
50. G.-l. Ming, and H. Song Adult neurogenesis in the mammalian brain: significant answers and significant questions Neuron 70 2011 687 702
51. J.C. Moeller, W.H. Oertel, J. Koester, G. Pezzoli, and L. Provinciali Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial Mov. Disord. 20 2005 602 610
52. S.A. Molloy, E.N. Rowan, J.T. O'Brien, I.G. McKeith, K. Wesnes, and D.J. Burn Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies J. Neurol. Neurosurg. Psychiatry 77 2006 1323 1328
53. I.-C. Mundiñano, M.-C. Caballero, C. Ordóñez, M. Hernandez, C. DiCaudo, I. Marcilla, M.-E. Erro, M.-T. Tuñon, and M.-R. Luquin Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders Acta Neuropathol. 122 2011 61 74
54. S. Nuber, E. Petrasch-Parwez, B. Winner, J. Winkler, S. von Horsten, T. Schmidt, J. Boy, M. Kuhn, H.P. Nguyen, P. Teismann, J.B. Schulz, M. Neumann, B.J. Pichler, G. Reischl, C. Holzmann, I. Schmitt, A. Bornemann, W. Kuhn, F. Zimmermann, A. Servadio, and O. Riess Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease J. Neurosci. 28 2008 2471 2484
55. G.C. O'Keeffe, R.A. Barker, and M.A. Caldwell Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain Cell Cycle 8 2009 2888 2894
56. G.C. O'Keeffe, P. Tyers, D. Aarsland, J.W. Dalley, R.A. Barker, and M.A. Caldwell Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF Proc. Natl. Acad. Sci. U. S. A. 106 2009 8754 8759
57. J.H. Park, and G. Enikolopov Transient elevation of adult hippocampal neurogenesis after dopamine depletion Exp. Neurol. 222 2010 267 276
58. M.F. Piercey Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease Clin. Neuropharmacol. 21 1998 141 151
59. R.D. Porsolt, M. Le Pichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatments Nature 266 1977 730 732
60. K. Pothakos, M.J. Kurz, and Y.S. Lau Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration BMC Neurosci. 10 2009 6
61. S.P. Presgraves, S. Borwege, M.J. Millan, and J.N. Joyce Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells Exp. Neurol. 190 2004 157 170
62. I. Rektorova, I. Rektor, M. Bares, V. Dostal, E. Ehler, Z. Fanfrdlova, J. Fiedler, H. Klajblova, P. Kulist'ak, P. Ressner, J. Svatova, K. Urbanek, and J. Veliskova Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy Eur. J. Neurol. 12 2005 9 15
63. P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system Brain 128 2005 1314 1322
64. G.W. Ross, H. Petrovitch, R.D. Abbott, C.M. Tanner, J. Popper, K. Masaki, L. Launer, and L.R. White Association of olfactory dysfunction with risk for future Parkinson's disease Ann. Neurol. 63 2008 167 173
65. B. Scatton, H. Simon, M. Le Moal, and S. Bischoff Origin of dopaminergic innervation of the rat hippocampal formation Neurosci. Lett. 18 1980 125 131
66. J.S. Schneider, E.Y. Pioli, Y. Jianzhong, Q. Li, and E. Bezard Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model Mov. Disord. 28 2013 663 667
67. J.S. Schneider, A. Yuwiler, and C.H. Markham Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP Brain Res. 411 1987 144 150
68. O. Schulte-Herbruggen, M.A. Vogt, H. Hortnagl, P. Gass, and R. Hellweg Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels of BDNF in mice Eur. J. Pharmacol. 677 2012 77 86
69. R.K. Schwarting, and J.P. Huston Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae Prog. Neurobiol. 49 1996 215 266
70. J.A. Siuciak, and R.A. Fujiwara The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors Psychopharmacology 175 2004 163 169
71. K. Stiasny-Kolster, Y. Doerr, J.C. Moller, H. Hoffken, T.M. Behr, W.H. Oertel, and G. Mayer Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT Brain 128 2005 126 137
72. K. Suzuki, K. Okada, T. Wakuda, C. Shinmura, Y. Kameno, K. Iwata, T. Takahashi, S. Suda, H. Matsuzaki, Y. Iwata, K. Hashimoto, and N. Mori Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine PLoS ONE 5 2010 e9260
73. M.T. Tadaiesky, P.A. Dombrowski, C.P. Figueiredo, E. Cargnin-Ferreira, C. Da Cunha, and R.N. Takahashi Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease Neuroscience 156 2008 830 840
74. U. Ungerstedt 6-Hydroxy-dopamine induced degeneration of central monoamine neurons Eur. J. Pharmacol. 5 1968 107 110
75. B. Winner, P. Desplats, C. Hagl, J. Klucken, R. Aigner, S. Ploetz, J. Laemke, A. Karl, L. Aigner, E. Masliah, E. Buerger, and J. Winkler Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model Exp. Neurol. 219 2009 543 552
76. B. Winner, M. Geyer, S. Couillard-Despres, R. Aigner, U. Bogdahn, L. Aigner, G. Kuhn, and J. Winkler Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb Exp. Neurol. 197 2006 113 121
77. P. Yang, S.A. Arnold, A. Habas, M. Hetman, and T. Hagg Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice J. Neurosci. 28 2008 2231 2241